A5048397469- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Prostate Cancer Treatment and Research
- Management of metastatic bone disease
- Sexual function and dysfunction studies
- COVID-19 and healthcare impacts
- Multiple and Secondary Primary Cancers
- Pancreatic and Hepatic Oncology Research
- Genital Health and Disease
- Tuberous Sclerosis Complex Research
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- Prostate Cancer Diagnosis and Treatment
- Bladder and Urothelial Cancer Treatments
- Bone health and treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Chemotherapy-related skin toxicity
- COVID-19 Clinical Research Studies
- PARP inhibition in cancer therapy
- Hormonal Regulation and Hypertension
- SARS-CoV-2 and COVID-19 Research
- Healthcare cost, quality, practices
City Clinical Oncology Center
2014-2024
Institute of Oncology NN Petrov
2021
Ministry of Health of the Russian Federation
2020-2021
Clinical Practice Points•One-half of patients with renal cell carcinoma infected severe acute respiratory syndrome coronavirus 2 required hospitalization.•Eastern Cooperative Oncology Group performance status could be negatively changed in these patients.•The mortality rate is higher than people without cancer.•Some have progression during infection. •One-half
Abstract Background To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of vaccination in Russian patients with genitourinary (GU) malignancies. Aim analysis was describe the characteristics infection course as well preliminary efficacy Gam-COVID-Vac vaccine active GU Methods Patients were retrospectively identified at nine cancer centers different regions. included if diagnosed by a polymerase chain reaction. Data from additional cancers who had positive...
Fatigue is one of the most common adverse events systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim multicenter randomized phase 2 study was to determine efficacy and safety testosterone fatigue developed during targeted therapy.Male clear-cell RCC, normal prostate-specific antigen level, low no evidence hypothyroidism receiving first-line sunitinib or pazopanib were randomly assigned (1:1) either undecanoate (1000 mg) alone. primary endpoint mean change from...
20 Background: The results of the 5-year overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) has been reported rarely. aim RENSUR5 registry study was to obtain real-world data on use therapies mRCC and assess OS Russian population. Methods: Patients were retrospectively identified at 11 cancer centers different regions Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St.Petersburg, Ufa). included if diagnosed from...
383 Background: Sexual activity is an important part of social functioning and quality life. Cancer diagnosis concomitant treatment has a damaging effect on sexual function. The objective this prospective study was to evaluate the incidence erectile dysfunction (ED) in men with metastatic renal cell carcinoma (mRCC) receiving first-line therapy. Methods: All patients were evaluated for function 5-item version International Index Erectile Function (IIEF-5) Functional Assessment Therapy-Kidney...
e16117 Background: Complete metastasectomy in patients with potentially surgically resectable metastases have an important role the management of metastatic renal cell carcinoma (mRCC).Clinical benefits incomplete (iME) can be assessed era targeted therapy. The aim present retrospective study was to evaluate preliminary efficacy iME and following Methods: Data collected from single center for clear mRCC at presentation treated therapy or medical treatment alone 2008-2015. Resection (patients...
Objective: an assessment of efficacy and safety lenvatinib in combination with everolimus unselected patients metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line antiangiogenic targeted therapy. Material. Russian multicenter observational study ROSLERCM included 73 consecutive morphologically verified mRCC therapy, treated (18 mg/d) (5 20 centers. Median age the was 59 (23–73) years, a male-to-female ratio – 3:1. Most common histological type kidney cancer...
Objective . To increase the effectiveness of drug treatment via systemic therapy (ST) in combination with incomplete cytoreductive interventions – metastasectomy (iME). Materials and methods Three centers took part study. All 147 patients mRCC received anticancer therapy. Part them (n = 47) underwent surgery (iME) before or together treatment, where iME meant complete metastasis excision within one organ residual tissue other organs (research group). Control group 100) included who only...
644 Background: an assessment of efficacy and safety lenvatinib in combination with everolimus unselected patients metastatic renal cell carcinoma (mRCC) progressed during or following ≥1 line antiangiogenic targeted therapy. Methods: Russian multicenter observational study included 73 consecutive morphologically verified mRCC therapy, treated (18 mg/d) (5 20 centers. Median age the was 59 (23-73) years, a male-to-female ratio - 3:1. Most common histological type kidney cancer clear-cell RCC...
Background. Experience with combination treatment, i.e. systemic therapy in palliative surgery, the treatment of metastatic kidney cancer is very rarely described world literature. Objective: to evaluate efficiency cytoreductive surgery and targeted define optimal indications for treatment. Subjects methods . Data on 47 patients renal cell carcinoma (mRCC) who received (targeted) or after incomplete cytoreduction (iCR) were analyzed this retrospective study. The proportion men women was 72.3...
Prostate cancer (PC) treatment is a pressing problem both inRussiaand worldwide. According to data for Saint-Petersburg, from 1990 2002 morbidity increase rate PC was 141.3 %. Even after nerve-sparing radical prostatectomy (RP) erectile dysfunction of some level observed in 65–75 % patients. During follow-up examination, on sexual history were gathered including information past and current contacts. A questionnaire based the International Index Erectile Function used which allows evaluate...
666 Background: Targeted therapy with axitinib resulted in a greater objective response rate and prolonged progression-free survival (PFS) compared to sorafenib patients previously treated metastatic renal cell carcinoma (mRCC) AXIS study. 75% of had intermediate poor IMDC prognosis. In this phase 2 study, we assessed the activity mRCC favourable risk history prior VEGFR-directed therapy. Methods: Patients were required have clear mRCC, according criteria, received first-line treatment...
574 Background: In multicenter randomized phase 2 study (FARETES) we showed that male patients with mRCC receiving targeted therapy had significantly less fatigue and better symptom control testosterone undecanoate (T) (MASCC 2018, LBA004). Here described exploratory endpoints in FARETES study. Methods: Sixty clear cell mRCC, normal PSA level, low level no evidence of hypothyroidism first-line sunitinib or pazopanib were randomly assigned (1:1) to either T (Nebido, 1,000 mg) alone (control...
Objective – to evaluate efficacy and safety of everolimus in Russian population unselected patients with advanced renal cell carcinoma progressing after at least 1 line anti-angiogenic targeted therapy. Materials methods . In observational multicenter study CRAD001LRU03 from 17.01.2012 31.03.2015 43 centers 226 documented progression on the background or therapy were included. The survey was conducted all according practice, administered accordance instructions drug. Results. response rate...
Renal cancer is one of the most rapidly spreading diseases in world. As you know, a few years ago, overall survival patients with metastatic renal cell carcinoma (mRCC) was disappointing: median rarely exceeded 13 months, while 5-year rate less than 5 %. Immunotherapy interferon-alpha and interleukins demonstrated low efficiency. Appearance targeted therapies for treatment mRCC significantly increased duration quality life receiving drug treatment. Nowadays due to this methodology guided by...
4569 Background: Fatigue is a frequent symptom of metastatic renal cell carcinoma (mRCC), and most common adverse event treatment with tyrosine kinase inhibitors. The aim this multicenter randomized phase 2 study was to determine efficacy safety testosterone undecanoate (T) in mRCC patients fatigue developed during targeted therapy. Methods: Sixty male clear mRCC, normal PSA level, low level no evidence hypothyroidism receiving first-line sunitinib or pazopanib were randomly assigned (1:1)...